The emergence of new drugs and the application of big data to develop treatments and biomarkers for early detection are developments that are transforming Alzheimer’s research and are addressed in the new book Neurodegeneration and Alzheimer’s.
Written by the director of the Pascual Maragall Foundation and the Barcelona Beta Brain Research Center (BBRC), Arcadi Navarro, and the neuropsychologist expert in training and awareness of the same entity, Dr. Nina Grammont, the book explores prevention methods and new medicines to combat the disease. illness
The work also analyzes how big data is transforming drug research and biomarker development. “In recent years, there has been a paradigm shift in understanding Alzheimer’s and other neurological diseases. We now have biomarkers that advance diagnosis and must be complemented by new drugs that for the first time modify the biological pathway of affected people,” says Dr. Gramont, referring mainly to a drug. Lecanimab, one of the most promising drugs in Alzheimer’s research by slowing its progression in patients in the early stages of the disease, which, despite getting the green light in the United States, Japan and China, has not yet been approved for use by an agency European Medicines This drug, at the moment, is the only effective drug when it comes to slowing its progression.
Big data, which allows working with large amounts of data to find the best combination, has greatly accelerated the search for biomarkers. “Now we can expect about 15 or 20 years before the first symptoms appear,” explains Arkady Navarro.
“Freelance social media evangelist. Organizer. Certified student. Music maven.”
